Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 11/20 | 0.38 |
| ▸ | GCK | P35557 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.34 |
| ▸ | IDH2 | P48735 | 1/20 | 0.33 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3968152 | 0.88 | CNR2 (0.53) | CNR2SMN1; SMN2CNR1LMNA | |
| SCHEMBL3963538 | 0.86 | CNR2 (0.39) | CNR2GCKCNR1 | |
| SCHEMBL1464422 | 0.81 | NPC1 (0.42) | SMN1; SMN2LMNAHTTKDM4EPOLB | |
| SCHEMBL1464477 | 0.81 | CNR2 (0.54) | CNR2SMN1; SMN2CNR1FFAR2IDH2 | |
| SCHEMBL1465823 | 0.75 | FFAR2 (0.48) | CNR2SMN1; SMN2CNR1LMNAHTT | |
| SCHEMBL1464662 | 0.73 | CNR2 (0.58) | CNR2SMN1; SMN2CNR1LMNAHTT | |
| SCHEMBL1465056 | 0.69 | FFAR2 (0.49) | CNR2CNR1FFAR2CTPS1 | |
| SCHEMBL1464679 | 0.69 | FFAR2 (0.51) | CNR2SMN1; SMN2CNR1LMNAHTT | |
| SCHEMBL1464407 | 0.69 | FFAR2 (0.60) | CNR2CNR1FFAR2 | |
| SCHEMBL1464798 | 0.69 | ADORA1 (0.56) | CNR2GCKSMN1; SMN2LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935715-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-03 | — | — | US | disclosed |
| US-20080039464-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039464-A1 | Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CNR2 1/4885GCK 2782/4885SMN1; SMN2 4576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.